Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Palliative care in heart, lung, renal and neurological disease
Palliative and end-of-life care · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
!
Acute organ-failure deterioration
Advanced chronic disease can still produce reversible pulmonary oedema, infection, bronchospasm, electrolyte disturbance, seizure or device shock. A palliative plan should accelerate proportionate relief, not replace acute assessment automatically.
Action: Use ABCDE care, identify the dominant mechanism and check the emergency plan and current capacity. Treat hypoxaemia, congestion, bronchospasm, sepsis, hyperkalaemia or seizure under the appropriate pathway when consistent with goals; involve the relevant specialty and palliative team and provide opioid or anxiolytic symptom relief without delaying reversible treatment.
Purpose and principles
Integrate palliative care early with active treatment for advanced cardiac, respiratory, kidney and neurological disease, managing symptom mechanisms, uncertain trajectories, treatment withdrawal and organ-specific medicine risks without relying on a cancer model.
People with non-malignant disease are often referred late because survival is difficult to predict and active treatment continues. This is a false choice. Specialist and generalist palliative care can address symptoms, decisions and family needs while cardiology, respiratory, renal and neurology teams continue treatments intended to prolong life or preserve function. Recurrent admissions, declining function, persistent symptoms and caregiver strain are practical referral triggers.
Start with mechanism and trajectory. Breathlessness may result from pulmonary congestion, airflow obstruction, interstitial restriction, anaemia, infection, pleural fluid, respiratory muscle weakness, anxiety or several processes. Fatigue may reflect low output, uraemia, sleep disturbance, medicines or depression. Review observations, examination and selected tests only when results could lead to treatment the person wants.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
Palliative and end-of-life careOriginal SBA
Managing refractory COPD breathlessness
A patient with advanced COPD remains severely breathless despite optimised inhalers, rehabilitation, fan use and assessment showing no acute exacerbation. Oxygen saturation is above the threshold for long-term oxygen. What is the best next approach?
Sources and review status6 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
NICE NG106 chronic heart failureSymptom assessment, medicines, monitoring, multidisciplinary care and palliative referral in heart failure.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem ·
Advanced heart failure produces exertional or resting breathlessness, oedema, ascites, fatigue and repeated congestion. Optimise loop diuretic to clinical fluid state and continue disease-modifying treatment while blood pressure, renal function, potassium and goals permit. Simplification near death should distinguish long-term prevention from medicines still relieving angina, arrhythmia or congestion. Discuss pacemaker dependency and deactivate the shock function of an implantable cardioverter-defibrillator when shocks would be unwanted; pacing can usually remain.
For COPD or interstitial lung disease, check inhaler technique, bronchodilator and anti-inflammatory treatment, infection, pulmonary rehabilitation, smoking support and reversible anxiety. A handheld fan, pacing, recovery position and breathing training are first measures for chronic breathlessness. Long-term oxygen follows disease-specific hypoxaemia assessment, not breathlessness alone. After optimal treatment, carefully titrated opioid may reduce refractory breathlessness with monitoring and a renal-appropriate choice.
Kidney supportive care includes symptom control, decision support and advance planning whether dialysis continues or not. Conservative kidney management is active multidisciplinary care for people who choose not to start dialysis or are unlikely to gain enough benefit. Address fluid, pruritus, nausea, restless legs, anaemia, acidosis and medicine toxicity. Decisions about dialysis initiation, trial, non-escalation or withdrawal should reflect informed preference, function, comorbidity and a defined goal rather than age alone.
Renal clearance materially changes palliative pharmacology. Morphine and codeine metabolites accumulate in severe impairment and can cause sedation, hallucinations and myoclonus. Gabapentin and pregabalin require large dose reductions. NSAIDs can worsen kidney function and fluid. Alfentanil or fentanyl may be selected by specialists for severe renal failure, but route, dose and breakthrough plan still depend on prior opioid exposure and setting.
Neurological conditions create distinctive losses: communication, swallowing, cough, mobility and cognition. In motor neurone disease, discuss non-invasive ventilation, gastrostomy and communication technology before crisis while avoiding rigid deadlines. Parkinson medicines should be given on time and converted with specialist advice when swallowing fails. Multiple sclerosis and advanced brain injury may require spasticity, bladder, pressure and seizure plans. Supported communication is essential for capacity assessment.
Withdrawing life-sustaining treatment is a treatment decision. A capacitous adult can refuse dialysis or ventilation. When capacity is absent, apply the relevant UK legal framework, previous wishes, any valid advance refusal and best-interests or benefit decision, with second opinion where disagreement persists. Plan the expected symptom trajectory, reliable medicine route, family presence and location before treatment stops; do not abandon disease-team involvement.
Review outcomes that matter to the person: sleeping flat, reaching the bathroom, communicating with family, avoiding shocks or remaining at home. A time-limited trial of intravenous diuresis, non-invasive ventilation or dialysis should state the desired recovery, duration and stopping rule. Reassess after each crisis, because preferences and acceptable burden can change in either direction.
Key points
Palliative care is based on need, not diagnosis or a precise prognosis, and should run alongside disease-modifying heart, lung, kidney and neurological treatment.
First-line assessment separates the symptom mechanism from the disease label: congestion, bronchospasm, hypoxaemia, uraemia, weakness, dysphagia, anxiety and deconditioning require different responses.
Organ failure often fluctuates through crises and partial recovery; discuss uncertainty and use repeated trigger-based planning rather than waiting for a predicted final week.
In heart failure, optimise congestion and guideline-directed treatment while tolerated, review hypotension and kidney injury and discuss implantable-defibrillator shock deactivation before dying.
In advanced lung disease, maximise inhaled treatment, rehabilitation and breathing techniques; use oxygen for qualifying hypoxaemia and consider low-dose opioid for refractory breathlessness after assessment.
In advanced kidney disease, offer shared choice between dialysis, conservative kidney management and time-limited dialysis, integrating symptom and future-care planning whichever route is chosen.
Severe renal impairment increases accumulation of morphine, codeine, gabapentinoids and several sedatives; choose and dose symptom medicines with renal and palliative expertise.
Indications, selection and cautions
Heart-failure burden
Orthopnoea, oedema, ascites, early satiety, hypotension and repeated congestion suggest symptoms remain partly haemodynamic and may respond to treatment adjustment.
Advanced lung limitation
Breathlessness at minimal activity, panic, frequent exacerbations, chronic hypoxaemia or hypercapnia and declining recovery signal need for parallel supportive planning.
Kidney supportive-care need
Pruritus, nausea, restless legs, cognitive change, fluid overload and treatment fatigue require renal symptom review and informed modality discussion.
Neurological dependency
Weak cough, dysphagia, communication loss, falls, pressure risk and caregiver exhaustion often emerge before the final phase and need anticipatory intervention.
Medicine accumulation
New drowsiness, hallucinations, myoclonus or slow breathing after kidney decline suggests opioid or sedative toxicity rather than inevitable disease progression.
Acute reversible crisisRed flag
Pulmonary oedema, severe exacerbation, sepsis, hyperkalaemia, prolonged seizure, aspiration or ventilatory failure requires immediate assessment within the agreed treatment ceiling.
Red flags requiring action
New chest pain, syncope, shock or recurrent implantable-defibrillator shocks requires urgent cardiac and device assessment.
Silent chest, exhaustion, severe hypoxaemia, hypercapnic drowsiness or
Assessment before treatment
01First-line symptom-mechanism assessmentFirst stepFirst line
Why
Define breathlessness, fluid, pain, fatigue, cognition, swallow, secretion, mobility and treatment adherence against the recent baseline.
Interpretation and limitations
Identifying the dominant reversible mechanism directs proportionate disease and symptom treatment rather than generic palliation.
02Targeted cardiorespiratory assessment
Why
Use ECG, chest imaging, oxygen measurement, blood gases, natriuretic peptide or lung function only when likely to change accepted treatment.
Interpretation and limitations
Congestion, infection, hypoxaemia, hypercapnia or bronchospasm may remain treatable; tests are burdensome when no corresponding intervention is wanted.
03Renal and electrolyte profile
Why
Measure filtration trend, potassium, bicarbonate, calcium and relevant drug exposure when dialysis, fluid or prescribing decisions depend on results.
Interpretation and limitations
Biochemistry guides urgent correction and medicine safety but does not alone determine dialysis benefit or prognosis.
04Swallow, cough and communication assessment
Why
Evaluate aspiration, secretion clearance, nutrition route, speech access and supported decision-making in progressive neurological disease.
Interpretation and limitations
Treatment approach
01Parallel careOptimise disease treatment and palliation togetherFirst stepAdvanced organ or neurological disease causes persistent symptoms, recurrent admissions or functional decline.+
1Identify treatable symptom mechanisms and optimise specialist therapy, rehabilitation, equipment and self-management within tolerance and goals.
2Introduce palliative support for refractory symptoms, communication, family needs and future planning without requiring cessation of disease treatment.
3Agree patient-valued outcomes and reassess after each crisis, documenting which active treatments remain proportionate.
02Organ-specific adaptationMatch symptom treatment to physiological reserveHeart, lung, kidney or neurological impairment changes usual palliative medicines or routes.+
1Review fluid, oxygenation, filtration, swallow, cough, cognition and current opioid, sedative, Parkinson and antiseizure exposure.
Regimens, contraindications and interactions
Can reduce the perception of persistent breathlessness in selected advanced heart or lung disease when non-drug and disease-directed treatment is insufficient.
Low-dose morphine trial for refractory breathlessness
For an opioid-naive adult after optimal disease treatment, a common Scottish palliative starting regimen is immediate-release oral morphine 2 mg as needed, initially no more often than every four hours, with early review before regular dosing.
Use a lower or alternative plan in frailty, hypercapnic vulnerability or kidney failure; monitor alertness, respiratory rate, nausea and constipation and never substitute it for emergency treatment.
Relieves pulmonary and peripheral congestion in advanced heart or kidney disease and can improve breathing, sleep and mobility quickly.
Loop diuretic for symptomatic congestion
Continue or adjust the person's established oral or intravenous loop-diuretic regimen to weight, oedema, blood pressure, renal function and response; use specialist home parenteral protocols where commissioned rather than an unmonitored standard dose.
Monitor hypotension, dehydration, kidney injury, sodium, potassium and access burden; apparent renal worsening may require expert interpretation rather than automatic cessation during effective decongestion.
Maintains analgesia or breathlessness control while reducing accumulation of active morphine or codeine metabolites in severe kidney impairment.
Complications, monitoring and follow-up
Track a patient-defined function alongside pain, breathlessness, oedema, pruritus, sleep and communication at every major review.
During diuretic adjustment review weight trend, congestion, pressure, renal function and electrolytes at a frequency matched to instability.
After opioid initiation or renal decline assess alertness, respiratory rate, hallucinations, myoclonus, nausea and bowel function promptly.
Review oxygen or ventilation for symptom and physiological benefit, interface burden, communication and changing goals.
Check Parkinson, antiseizure, steroid and baclofen continuity whenever oral intake or care setting changes.
Revisit dialysis, defibrillator and ventilation preferences after admissions, functional loss or a change in caregiver capacity.
Document the outcome of every time-limited trial and prevent an expired trial from becoming indefinite treatment by default.
Special situations
Need outranks prognosis
Uncertain survival in organ failure is a reason for earlier parallel palliative care, not a reason to postpone it.
Breathlessness has layers
Congestion, airflow obstruction, muscle weakness, fear and deconditioning can coexist and each requires a different intervention.
Oxygen is not a synonym for comfort
It treats qualifying hypoxaemia, while fan, pacing, rehabilitation and opioid may better address non-hypoxaemic refractory breathlessness.
Kidney failure rewrites doses
A familiar opioid or gabapentinoid regimen can become toxic within days as filtration and oral intake decline.
Shock and pacing differ
An implantable defibrillator's painful shock function can be disabled while useful bradycardia pacing is retained.
Withdrawal is not abandonment
Stopping dialysis or ventilation after a lawful decision requires more preparation and continuity, not less clinical attention.
Common pitfalls
01
Waiting for a precise six-month prognosis before referring non-cancer disease for palliative care.
02
Attributing all breathlessness to progression without checking congestion, infection, hypoxaemia and bronchospasm.
03
Giving oxygen for every breathless episode without assessing hypoxaemia or individual benefit.
04
Using morphine or codeine repeatedly in severe kidney failure without toxicity review.
05
Stopping beneficial diuresis solely because creatinine changed without interpreting congestion and goals.
06
Allowing an implantable defibrillator to deliver unwanted shocks during dying.
07
Omitting basal Parkinson or antiseizure treatment when swallowing fails.
08
Discussing gastrostomy, ventilation or communication technology only after the person can no longer participate.
09
Starting a burdensome treatment trial without a valued endpoint and review date.
10
Withdrawing dialysis or ventilation before symptom medicines, location, staffing and family support are ready.
Neurological disease requires early communication support, swallow and secretion planning, equipment, caregiver review and discussion of ventilation, gastrostomy and treatment withdrawal while the person can participate.
Continue essential Parkinson and antiseizure treatment through a feasible route; abrupt withdrawal can cause life-threatening deterioration mistaken for dying.
A decision to stop dialysis or assisted ventilation requires capacity or best-interests assessment, anticipatory symptom treatment and continuity of care; it is withdrawal of a burdensome treatment, not assisted dying.
stridor
indicates respiratory emergency.
Hyperkalaemic ECG change, severe fluid overload, uraemic pericarditis or encephalopathy needs immediate renal decision-making.
New choking, weak cough, aspiration or inability to manage secretions requires urgent airway and swallow review.
Abrupt cessation of levodopa, baclofen, corticosteroid or antiseizure treatment can cause dangerous withdrawal syndromes.
Increasing sedation, myoclonus or hallucinations after renal decline suggests medicine accumulation.
Stopping dialysis or ventilation without an agreed symptom, location and after-hours plan risks severe avoidable distress.
Early impairment supports communication aids, gastrostomy or ventilation discussion; assessment should not remove chosen oral pleasure automatically.
05Treatment-burden and function review
Why
Measure admissions, dialysis or ventilation burden, mobility, self-care, sleep and a patient-defined outcome over time.
Interpretation and limitations
Persistent burden without valued recovery triggers a shared review rather than automatic continuation or withdrawal.
06Device and life-sustaining treatment review
Why
Identify defibrillator settings, pacing dependency, dialysis prescription, non-invasive ventilation and any advance decision concerning treatment.
Interpretation and limitations
Technical facts and lawful preferences enable safe modification or withdrawal with anticipatory symptom planning.
2
Select organ-appropriate medicine and non-drug treatment with renal, respiratory, neurology, cardiology, pharmacy or palliative input as needed.
3Monitor the named benefit and early toxicity and revise promptly when filtration, alertness, swallowing or ventilation changes.
03Time-limited treatment trialTest whether a burdensome intervention restores a valued outcomeBenefit from dialysis, ventilation, intravenous diuresis or hospital treatment is uncertain but plausible.+
1Explain alternatives and agree a measurable goal, treatment duration, ceiling and signs that burden is exceeding benefit.
2Deliver the trial with full symptom and family support and collect functional and clinical outcomes rather than biochemistry alone.
3At the preset review, continue, modify or withdraw according to the agreed goal and current informed preference or lawful decision process.
04Treatment withdrawalStop life-sustaining treatment without stopping careA capacitous person refuses treatment or a lawful decision finds its burdens now outweigh likely benefit.+
1Confirm capacity, voluntariness, informed choice, advance documents and jurisdictional requirements and resolve uncertainty with senior second opinion.
2Plan location, timing, device or dialysis steps, expected symptoms, non-oral medicines, staffing, emergency contacts and family communication before withdrawal.
3Continue intensive comfort, review and bereavement support, documenting that symptom-proportionate treatment is distinct from intending death.
Renal-appropriate opioid substitution
When estimated glomerular filtration is below about 30 mL/min/1.73 m² and regular opioid is required, seek specialist conversion to an appropriate fentanyl or alfentanil regimen based on current total opioid exposure and route.
Conversions are high risk and not milligram equivalent; monitor sedation, delirium, myoclonus and respiratory rate and retain a separately calculated breakthrough prescription.